Publications by authors named "Peter Hertel"

Claim this Profile
E
Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension.
John M Kane, Bruce J Kinon, Carlos Forray, Pedro Such, Aurélia Mittoux, Peter Hertel

Schizophr Res· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study.
Joseph R Calabrese, Raymond Sanchez, Na Jin, Joan Amatniek, Kevin Cox, Peter Hertel

J Affect Disord· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study.
Joseph R Calabrese, Na Jin, Brian Johnson, Pedro Such, Ross A Baker, Peter Hertel

Int J Bipolar Disord· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study.
Dieter Naber, Ross A Baker, Anna Eramo, Carlos Forray, Karina Hansen, Peter Hertel

Schizophr Res· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder.
Joseph R Calabrese, Raymond Sanchez, Na Jin, Joan Amatniek, Kevin Cox, Peter Hertel

J Affect Disord· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study.
Steven G Potkin, Jean-Yves Loze, Carlos Forray, Ross A Baker, Christophe Sapin, Peter Hertel

PLoS One· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores.
Zahinoor Ismail, Timothy Peters-Strickland, Maia Miguelez, Ross A Baker, Peter Hertel

J Clin Psychopharmacol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY.
Steven G Potkin, Jean-Yves Loze, Carlos Forray, Ross A Baker, Christophe Sapin, Peter Hertel

Int Clin Psychopharmacol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration.
Arash Raoufinia, Timothy Peters-Strickland, Anna-Greta Nylander, Ross A Baker, Anna Eramo, Peter Hertel

Int J Neuropsychopharmacol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study.
Joseph R Calabrese, Raymond Sanchez, Na Jin, Joan Amatniek, Kevin Cox, Peter Hertel

J Clin Psychiatry· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate.
Steven G Potkin, Jean-Yves Loze, Carlos Forray, Ross A Baker, Christophe Sapin, Peter Hertel

Int J Neuropsychopharmacol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.
Dieter Naber, Karina Hansen, Carlos Forray, Ross A Baker, Christophe Sapin, Peter Hertel

Schizophr Res· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
John M Kane, Timothy Peters-Strickland, Ross A Baker, Peter Hertel, Anna Eramo

J Clin Psychiatry· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes and risks of operative treatment of rupture of the anterior cruciate ligament in children and adolescents.
Karl-Heinz Frosch, Dirk Stengel, Tobias Brodhun, Immanuel Stietencron, Dirk Holsten, Peter Hertel

Arthroscopy· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relevance of dorsal raphe nucleus firing in serotonin 5-HT(2C) receptor blockade-induced augmentation of SSRIs effects.
Florence Sotty, Joost H A Folgering, Lise T Brennum, Sandra Hogg, Arne Mørk, Peter Hertel

Neuropharmacology· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lu 35-138 ((+)-(S)-3-{1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)ethyl]-3,6-dihydro-2H-pyridin-4-yl}-6-chloro-1H-indole), a dopamine D4 receptor antagonist and serotonin reuptake inhibitor: characterisation of its in vitro profile and pre-clinical antipsychotic potential.
Peter Hertel, Michael Didriksen, Bruno Pouzet, Lise T Brennum, Karina K Søby

Eur J Pharmacol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action.
Peter Hertel

Synapse· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex.
Asa Konradsson, Monica M Marcus, Peter Hertel, Torgny H Svensson, Kent E Jardemark

Synapse· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat.
Monica M Marcus, Kent E Jardemark, Marie-Louise Wadenberg, Xavier Langlois, Peter Hertel

Int J Neuropsychopharmacol· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tensile properties of an anterior cruciate ligament graft after bone-patellar tendon-bone press-fit fixation.
Volker Musahl, Steven D Abramowitch, Mary T Gabriel, Richard E Debski, Peter Hertel

Knee Surg Sports Traumatol Arthrosc· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repeated administration of the neurotensin analogue NT69L induces tolerance to its suppressant effect on conditioned avoidance behaviour.
Peter Hertel, Christina Kurre Olsen, Jørn Arnt

Eur J Pharmacol· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis